Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Down 5.3 %

Shares of NASDAQ ADXS opened at $0.03 on Wednesday. The stock has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.62. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The stock has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.04.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.